Pharma Tech

China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway

Aug 6, 2026, 9:33 AM

Read Full Article → China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway

Translate article text

Choose a language and wait for the translated text.

China is becoming a global hub for oncology trials, with the NMPA now offering expedited review pathways for INDs.